IP Library Granted Patent US 11,975,027
Granted Patent B2
US 11,975,027 · App. 17/539,155 · Granted May 7, 2024

Tumoricidal and antimicrobial compositions and methods

Inventors: Hans G. Klingemann (Boston, MA); Barry J. Simon (Culver City, CA)
Assignee: ImmunityBio, Inc.
A61K35/17A61K9/0014A61K9/0019A61K9/06A61K9/08A61K9/5068A61K38/2013C12N5/0646A61K2035/124
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,975,027
App. No.
17/539,155
Granted
May 7, 2024
Kind
B2
Abstract

Provided herein are pharmaceutical compositions comprising tumoricidal and/or antimicrobial components isolated from the supernatant of NK-92 cell medium and methods of using the compositions for killing cancer cells.

Claims (8)

1. A composition comprising isolated exosomes or microvesicles from NK-92 cells cultured in a medium supplemented with at least one of a nutrient, a cytokine, or a growth factor, wherein the isolated exosomes or microvesicles are anti-bacterial and anti-viral.

2. The composition of claim 1 , wherein the medium comprises a cytokine and the cytokine is selected from the group consisting of IL-2, IL-15, interferon gamma and combinations thereof.

3. The composition of claim 1 , wherein the medium comprises a nutrient.

4. The composition of claim 1 , wherein the medium comprises a growth factor.

5. The composition of claim 1 , wherein the composition further comprises a cytokine, chemotherapy, cell-based therapy, or antibody therapy.

6. The composition of claim 1 , wherein the medium comprises L-asparagine, L-glutamine, L-serine or combinations thereof.

7. The composition of claim 1 , wherein the isolated exosomes or microvesicles are anti-bacterial.

8. The composition of claim 1 , wherein the isolated exosomes or microvesicles are anti-viral.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 13, 2024
From: KLINGEMANN, HANS G.; SIMON, BARRY J.
To: NANTKWEST, INC.
Reel/Frame 066752/0373 →
CHANGE OF NAME Recorded Mar 13, 2024
From: NANTKWEST, INC.
To: IMMUNITYBIO, INC.
Reel/Frame 066804/0258 →
SECURITY INTEREST Recorded Jan 2, 2024
From: IMMUNITYBIO, INC.; NANTCELL, INC.; RECEPTOME, INC.; VBC HOLDINGS LLC; ALTOR BIOSCIENCE, LLC; ETUBICS CORPORATION; IGDRASOL, INC.
To: INFINITY SA LLC, AS PURCHASER AGENT
Reel/Frame 066179/0074 →
Continuity (5)
Continuation 16598418 · Oct 10, 2019
Continuation 16289494 · Feb 28, 2019
Division 15032518
Provisional Application 61899066 · Nov 1, 2013
Related Publication 20220160768A1 · May 26, 2022